1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.
1alpha,25-Dihydroxyvitamin D3 (1,25D3) exhibits antitumor activity in a variety of cancers including squamous cell carcinoma (SCC). Intrinsic resistance of SCC cells to cisplatin was observed and led to the investigation into whether 1,25D3 sensitizes SCC cells to cisplatin. Pretreatment with 1,25D3 followed by cisplatin enhanced growth inhibition in SCC cells compared with 1,25D3 alone as assessed by cytotoxicity and in vitro clonogenic assays. In addition, 1,25D3 sensitized SCC cells to cisplatin-mediated apoptosis. Treatment of tumor-bearing C3H mice with 1,25D3 before cisplatin reduced clonogenic survival using in vivo excision clonogenic assay. These results were not observed in a 1,25D3-resistant SCC variant, indicating the critical role of 1,25D3 in sensitizing SCC cells to cisplatin. Further, a marked decrease in fractional tumor volume was observed when SCC tumor-bearing mice were treated with 1,25D3 before cisplatin compared with either agent administered alone. Cisplatin has been shown to modulate p73 protein level in certain cancer cells. Our data showed that p73 level was not affected by cisplatin but increased by 1,25D3 in SCC cells. Knocking down p73 by small interfering RNA protected SCC cells against 1,25D3 and cisplatin-mediated clonogenic cell kill and apoptosis. Increasing p73 protein level by knocking down UFD2a, which mediates p73 degradation, promoted 1,25D3 and cisplatin-mediated clonogenic cell kill. These results suggest that 1,25D3 potentiates cisplatin antitumor activity in vitro and in vivo in a SCC model system possibly through p73 induction and apoptosis. The combination treatment may provide a more effective therapeutic regimen in cancer treatment.
Ma
Yingyu
Y
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
Yu
Wei-Dong
WD
Hershberger
Pamela A
PA
Flynn
Geraldine
G
Kong
Rui-Xian
RX
Trump
Donald L
DL
Johnson
Candace S
CS
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D051379:Mice; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism*; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000494:pharmacology
D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; C000606368:Trp73 protein, mouse; D000072160:Tumor Protein p73; D025521:Tumor Suppressor Proteins; C118756:dihydroxy-vitamin D3; D014807:Vitamin D; D002945:Cisplatin
Oncogene. 2005 Nov 3;24(48):7156-69
16170377
Radiat Res. 1985 Oct;104(1):47-65
4048394
Cell Death Differ. 2006 Jun;13(6):935-40
16557273
Prog Nucleic Acid Res Mol Biol. 2001;67:93-130
11525387
Trends Biochem Sci. 1995 Oct;20(10):435-9
8533159
Am J Otolaryngol. 1997 Sep-Oct;18(5):293-8
9282244
Cell Death Differ. 2006 Jun;13(6):962-72
16601753
Cancer Res. 1997 Sep 1;57(17):3759-64
9288784
Nat Rev Drug Discov. 2005 Apr;4(4):307-20
15789122
Clin Cancer Res. 2001 Apr;7(4):1043-51
11309356
Biochem Pharmacol. 2004 Apr 15;67(8):1459-68
15041463
Cancer Res. 2007 Aug 15;67(16):7723-30
17699776
Cancer Res. 2005 Apr 1;65(7):2787-94
15805279
Oncogene. 2003 Oct 20;22(47):7265-79
14576837
Clin Cancer Res. 2003 Nov 15;9(15):5642-51
14654547
Science. 1998 Aug 28;281(5381):1317-22
9721090
Cancer Res. 1991 Oct 15;51(20):5454-60
1913664
Clin Cancer Res. 2001 Dec;7(12):4164-73
11751517
Am J Physiol. 1999 Aug;277(2):F157-75
10444570
Cancer Res. 2005 Mar 15;65(6):2186-92
15781630
Cancer Res. 1994 Oct 15;54(20):5380-6
7923169
Cancer Lett. 2007 Mar 8;247(1):122-9
16644109
Int J Oncol. 2002 Feb;20(2):355-60
11788901
Blood. 2001 Nov 1;98(9):2603-14
11675328
Cancer Cell. 2005 Apr;7(4):363-73
15837625
Nat Rev Cancer. 2002 Aug;2(8):605-15
12154353
Br J Cancer. 2004 Sep 13;91(6):1025-31
15292937
J Biol Chem. 2001 Jul 13;276(28):26365-73
11331275
Cancer Res. 2006 Aug 15;66(16):8131-8
16912191
Oncogene. 2000 Nov 9;19(47):5413-8
11103943
Mol Pharmacol. 2001 Dec;60(6):1153-60
11723219
Mol Cancer Ther. 2002 Aug;1(10):821-9
12492115
Mol Cancer Ther. 2006 May;5(5):1209-15
16731753
Nat Rev Cancer. 2007 Sep;7(9):684-700
17721433
Cancer Res. 1988 Nov 1;48(21):6011-6
3262418
Nature. 1999 Jun 24;399(6738):806-9
10391249
Nat Rev Cancer. 2007 Aug;7(8):573-84
17625587
Arch Pharm Res. 2006 Feb;29(2):152-8
16526280
J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):519-26
15225831
J Natl Cancer Inst. 1998 Jan 21;90(2):134-41
9450573
Cancer Chemother Pharmacol. 1993;32(5):339-46
8339383
Blood. 2006 Nov 15;108(10):3450-7
16741250
Cancer Res. 1999 Jun 1;59(11):2644-9
10363987
Cancer Res. 1991 Jun 1;51(11):2848-53
2032225
J Biol Chem. 2004 Feb 27;279(9):8076-83
14634023
Oncogene. 1995 Oct 5;11(7):1217-28
7478541
Neoplasia. 2006 Aug;8(8):655-66
16925948
Curr Opin Oncol. 2007 May;19(3):216-21
17414639